Genscript Biotech Corporation (GNNSF)
USD 1.5
(-21.0%)
USD 1.5
(-21.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -415.79 Million USD | 10.32% |
| 2022 | -436.03 Million USD | 12.27% |
| 2021 | -497.04 Million USD | -140.54% |
| 2020 | -206.63 Million USD | -84.34% |
| 2019 | -112.09 Million USD | -599.68% |
| 2018 | 22.43 Million USD | -40.12% |
| 2017 | 37.46 Million USD | 15.2% |
| 2016 | 32.51 Million USD | 124.64% |
| 2015 | 14.47 Million USD | 75.53% |
| 2014 | 8.24 Million USD | -3.99% |
| 2013 | 8.59 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -75.38 Million USD | 0.0% |
| 2024 Q1 | -75.38 Million USD | 56.25% |
| 2023 Q2 | -217.96 Million USD | -95.87% |
| 2023 Q1 | -111.28 Million USD | 59.1% |
| 2023 FY | -391.01 Million USD | 10.32% |
| 2023 Q4 | -172.32 Million USD | -78.37% |
| 2023 Q3 | -96.61 Million USD | 55.68% |
| 2022 Q3 | -130.37 Million USD | 18.89% |
| 2022 Q2 | -160.73 Million USD | -81.38% |
| 2022 Q1 | -88.61 Million USD | 54.75% |
| 2022 FY | -436.03 Million USD | 12.27% |
| 2022 Q4 | -272.06 Million USD | -108.68% |
| 2021 Q4 | -195.84 Million USD | -72.58% |
| 2021 Q1 | -76.16 Million USD | 36.99% |
| 2021 FY | -497.04 Million USD | -140.54% |
| 2021 Q3 | -113.48 Million USD | 25.46% |
| 2021 Q2 | -152.23 Million USD | -99.89% |
| 2020 Q4 | -120.87 Million USD | -101.71% |
| 2020 Q2 | -82.91 Million USD | -95.79% |
| 2020 Q1 | -42.35 Million USD | 53.96% |
| 2020 FY | -206.63 Million USD | -84.34% |
| 2020 Q3 | -59.92 Million USD | 27.73% |
| 2019 Q3 | -45.14 Million USD | -8.03% |
| 2019 Q4 | -91.99 Million USD | -103.79% |
| 2019 FY | -112.09 Million USD | -599.68% |
| 2019 Q1 | -20.53 Million USD | -302.08% |
| 2019 Q2 | -41.78 Million USD | -103.52% |
| 2018 Q3 | -5.1 Million USD | -166.65% |
| 2018 Q2 | 7.66 Million USD | 0.0% |
| 2018 Q4 | -5.1 Million USD | 0.0% |
| 2018 Q1 | 7.66 Million USD | -27.27% |
| 2018 FY | 22.43 Million USD | -40.12% |
| 2017 Q3 | 10.53 Million USD | 13.76% |
| 2017 FY | 37.46 Million USD | 15.2% |
| 2017 Q4 | 10.53 Million USD | 0.0% |
| 2017 Q2 | 9.26 Million USD | 0.0% |
| 2017 Q1 | 9.26 Million USD | 73.85% |
| 2016 Q1 | 7.14 Million USD | 283.36% |
| 2016 FY | 32.51 Million USD | 124.64% |
| 2016 Q4 | 5.32 Million USD | 0.0% |
| 2016 Q3 | 5.32 Million USD | -25.4% |
| 2016 Q2 | 7.14 Million USD | 0.0% |
| 2015 Q3 | 1.86 Million USD | -48.09% |
| 2015 Q1 | 3.58 Million USD | 141.94% |
| 2015 Q4 | 1.86 Million USD | 0.0% |
| 2015 FY | 14.47 Million USD | 75.53% |
| 2015 Q2 | 3.58 Million USD | 0.0% |
| 2014 Q1 | 2.07 Million USD | 0.0% |
| 2014 FY | 8.24 Million USD | -3.99% |
| 2014 Q4 | 1.48 Million USD | 0.0% |
| 2014 Q3 | 1.48 Million USD | -28.5% |
| 2014 Q2 | 2.07 Million USD | 0.0% |
| 2013 FY | 8.59 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -31035.341% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -8142.49% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -2229.753% |
| Nascent Biotech, Inc. | -2.22 Million USD | -18546.348% |
| Rebus Holdings, Inc. | -664 Thousand USD | -62519.127% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 607.98% |
| Qrons Inc. | -643.67 Thousand USD | -64496.218% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -106630.754% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -649.065% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -99975.094% |
| Skye Bioscience, Inc. | -13.67 Million USD | -2941.231% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -479.209% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 8559.959% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -158764.996% |
| SQZ Biotechnologies Company | -75.82 Million USD | -448.356% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -14486.563% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -26968.863% |
| Mesoblast Limited | -84.14 Million USD | -394.125% |
| Marizyme, Inc. | -34.08 Million USD | -1119.811% |
| Genus plc | 6.4 Million USD | 6596.734% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 4367.824% |
| Pharming Group N.V. | -4.87 Million USD | -8421.104% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -20831.054% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -44542.466% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -4879.533% |
| ContraFect Corporation | -56.88 Million USD | -630.881% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -9028.782% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -29557.18% |
| IMV Inc. | -38.67 Million USD | -975.187% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -15015.061% |
| MultiCell Technologies, Inc. | -722.81 USD | -57524145.652% |
| ONE Bio Corp. | 13.68 Million USD | 3139.064% |
| Accustem Sciences Inc. | -3.74 Million USD | -10998.358% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -604.85% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -85974.044% |
| Q BioMed Inc. | -3.44 Million USD | -11967.247% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 11845.508% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -15724.454% |
| Biomind Labs Inc. | -1 Million USD | -41083.614% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -656.364% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -14231.443% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -6154.363% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -22201.957% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -1388091.106% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -2520.025% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -21414.48% |
| GB Sciences, Inc. | -1.42 Million USD | -29170.564% |
| Alpha Cognition Inc. | -9.7 Million USD | -4184.031% |
| HST Global, Inc. | -140.9 Thousand USD | -294981.863% |
| CSL Limited | 3.7 Billion USD | 111.232% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -36862.288% |
| Halberd Corporation | -75.05 Thousand USD | -553918.654% |
| Enzolytics Inc. | -2.14 Million USD | -19249.916% |
| Agentix Corp. | -1.37 Million USD | -30210.857% |
| Resverlogix Corp. | -12.74 Million USD | -3161.362% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -13023.581% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 2.178% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -39726.724% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -14142.13% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -26226.633% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -12111.265% |
| AVAX Technologies, Inc. | 6.69 Million USD | 6312.438% |
| Zenith Capital Corp. | -8.94 Million USD | -4549.346% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -2386622.921% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -16834.31% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -242330.246% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -20640.219% |
| Kadimastem Ltd | -3.04 Million USD | -13576.211% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -42152.907% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -33004.379% |
| BioStem Technologies, Inc. | -7.77 Million USD | -5245.066% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -229004.885% |
| LadRx Corporation | -3.82 Million USD | -10774.259% |
| Cell Source, Inc. | -4.32 Million USD | -9512.896% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -60427.113% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -60427.113% |
| NovAccess Global Inc. | -2.46 Million USD | -16755.754% |
| Affymax, Inc. | -15.04 Million USD | -2663.465% |
| Itoco Inc. | -919.14 Thousand USD | -45136.961% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -9710.061% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -37057.373% |
| Mobile Lads Corp. | -554.55 Thousand USD | -74878.09% |
| CytoDyn Inc. | -18.05 Million USD | -2202.531% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -1651830.87% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -188828.925% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -73527.424% |
| SYBLEU INC | -149.18 Thousand USD | -278617.657% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -22791.946% |
| International Stem Cell Corporation | -663 Thousand USD | -62613.575% |
| Bioxytran, Inc. | -3.82 Million USD | -10784.162% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -789776.52% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -2044103.54% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -1046.504% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -25597.837% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -56406.01% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -13265.188% |
| Neutra Corp. | -229.48 Thousand USD | -181083.602% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -2270.665% |
| PureTech Health plc | -146.19 Million USD | -184.401% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -1834.711% |
| IXICO plc | -1.43 Million USD | -28834.656% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -4280.898% |
| Gelesis Holdings, Inc. | -121.8 Million USD | -241.355% |
| CSL Limited | 3.81 Billion USD | 110.907% |
| Cellectis S.A. | -108.85 Million USD | -281.96% |